CIK 0000906709
- Non-accelerated filer
- Smaller reporting company
NEKTAR THERAPEUTICS
Sign in to watch- Ticker
- NKTR
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 943134940
- Phone
- +1 415-482-5300
- Business address
- 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA, 94158
- Former names
- INHALE THERAPEUTIC SYSTEMS INC, INHALE THERAPEUTIC SYSTEMS
- 4 Open-market sale Chief R&D Officer sold 9,703 shares at $0.78 ($7,568)
- 4 Open-market sale Chief Legal Officer sold 7,221 shares at $0.78 ($5,632)
- 4 Open-market sale President & CEO sold 19,998 shares at $0.78 ($15,598)
- 4 Planned sale Director sold 30,000 shares at $0.57 ($17,100)
- 4 Open-market sale Chief R&D Officer sold 9,791 shares at $0.72 ($7,050)
- 4 Open-market sale Chief Legal Officer sold 7,543 shares at $0.72 ($5,431)
- 4 Open-market sale President & CEO sold 20,361 shares at $0.72 ($14,660)
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale Chief R&D Officer sold 10,484 shares at $3.00 ($31,452)
- 4 Open-market sale Chief Legal Officer sold 8,275 shares at $3.00 ($24,825)
- 4 Open-market sale Chief Financial Officer sold 10,267 shares at $3.00 ($30,801)
- 4 Open-market sale President & CEO sold 19,635 shares at $3.00 ($58,905)
- 4 Open-market sale Chief R&D Officer sold 13,460 shares at $3.57 ($48,052)
- 4 Open-market sale Chief Legal Officer sold 8,690 shares at $3.57 ($31,023)
- 4 Open-market sale Chief Financial Officer sold 11,095 shares at $3.57 ($39,609)
- 4 Open-market sale President & CEO sold 38,014 shares at $3.57 ($135,710)
- 4 Open-market sale Director sold 4,198 shares at $3.16 ($13,266)
- 4 Open-market sale Director sold 4,198 shares at $3.16 ($13,266)
- 4 Open-market sale Director sold 5,100 shares at $3.19 ($16,269)
- 4 Grant or award Director acquired 10,200 shares (grant or award)
Page 5 of 49 · 968 filings